Dublin headquartered drugs group Icon grew its revenues by 12.5 per cent to $1.5 billion (€1.3 billion) in 2014, thanks to strong growth in the fourth quarter.
The global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries won new business of $1.8 billion in the year ended December 31st, 2014 pushing Q4 pre-tax profits up to $60.6 million. Pre-tax profits for the full year 2014 were $211.1 million.
CEO Ciaran Murray said the companfurther consolidated its position as a leader in the drug development industry in 2014.
“This has enabled us to book $1.8 billion of new business, to grow our closing backlog by 16 per cent to $3.6 billion and drive revenues by 13 per cent to over $1.5 billion. By continuing to improve our operational performance and expand our margins we increased EPS by 62 per cent to $2.87,” he said.
Icon is forecasting revenue to be in the range of $1.6-1.675 billion for 2015, an increase of 7-11 per cent, and earnings to be in the range $3.45- $3.60, an increase of 20-25 per cent.
